Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. HYPR
HYPR logo

HYPR Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
1.260
Open
1.260
VWAP
1.22
Vol
889.29K
Mkt Cap
121.11M
Low
1.191
Amount
1.09M
EV/EBITDA(TTM)
--
Total Shares
99.27M
EV
98.42M
EV/OCF(TTM)
--
P/S(TTM)
7.23
Hyperfine, Inc. is a health technology company. The Company is engaged in providing patient care globally through artificial intelligence (AI)-powered portable ultra-low-field (ULF) magnetic resonance (MR) brain imaging. Its Swoop Portable MR Imaging System (Swoop system) produces images at a lower magnetic field strength than conventional magnetic resonance imaging (MRI) scanners. Its Swoop system is designed to transform brain MR for the patient, the clinician and the provider, enabling a highly differentiated experience for patients, timely imaging for clinicians, and favorable economics for hospital administrators. The Swoop system is a portable ULF MRI device for producing images that display the internal structures of the head where full diagnostic examination is not clinically practical. The Swoop system is FDA-cleared for brain imaging of patients of all ages. The Swoop system is commercially available in a select number of international markets.
Show More

Events Timeline

(ET)
2026-07-01
08:30:00
Hyperfine Launches Next-Gen Swoop System in Europe
select
2026-06-22 (ET)
2026-06-22
08:30:00
Hyperfine Forms Neurosurgery Advisory Council
select
2026-06-18 (ET)
2026-06-18
08:30:00
Hyperfine Achieves 500 Scan Milestone for Swoop System in U.S. Hospitals
select
2026-05-12 (ET)
2026-05-12
16:50:00
Hyperfine Files to Sell 1.08M Shares of Class A Common Stock
select
2026-05-12
16:10:00
Management Expects 2026 Cash Burn of $26M-$28M
select

News

Newsfilter
8.5
07-01Newsfilter
Hyperfine Launches Next-Gen Swoop® System in Europe
  • Global Expansion Milestone: Hyperfine has launched the next-generation Swoop® system in European markets, marking a significant milestone in the global expansion of its advanced portable MRI technology, which is expected to enhance international commercial growth and improve global access to high-quality brain imaging.
  • Technological Advancement: The next-gen Swoop® system, powered by the latest Optive AI™ software, delivers transformative image quality that enables faster decision-making support in clinical settings, particularly in remote healthcare services.
  • Market Access: The Swoop® system has received CE mark and UKCA approval and has been included in the UniHA procurement listing within the French public healthcare system, which is anticipated to facilitate broader adoption across hospitals and further drive market penetration.
  • Commercialization Strategy: Hyperfine plans to make the Model 2 Swoop® system available through distribution partners across all European markets by 2026, which is expected to accelerate its usage and adoption in the U.S., thereby enhancing the company's competitiveness in the global medical imaging market.
Newsfilter
7.5
06-22Newsfilter
Hyperfine Forms Neurosurgery Advisory Council to Enhance Swoop® System Integration
  • Advisory Council Formation: Hyperfine has established a Neurosurgery Advisory Council comprising leading neurosurgeons worldwide to evaluate the potential applications of the Swoop® system in neurosurgery, thereby driving the clinical integration and advancement of portable MRI technology.
  • Technological Innovation: The Swoop® system, as the first FDA-cleared portable ultra-low-field MRI, provides real-time imaging during surgical procedures, enabling clinical teams to make more informed decisions, enhance surgical efficiency, and improve patient care quality.
  • Expert Participation: The council includes neurosurgery experts from renowned medical centers globally, covering various fields such as craniotomy and endovascular neurosurgery, ensuring a multidimensional evaluation of the Swoop® system and sharing of best practices.
  • Market Prospects: By collaborating with leading experts in the neurosurgery field, Hyperfine aims to accelerate the application of portable MRI in neurosurgical workflows, expanding its clinical utility to meet the growing healthcare demands.
Newsfilter
7.5
06-18Newsfilter
Accelerating Clinical Use of Portable MRI System
  • Clinical Milestone Achieved: Hyperfine's Swoop® system has surpassed 1,000 scans in key hospitals and neurology clinics across the U.S., indicating a significant increase in clinical utilization and adoption, thereby promoting the widespread use of portable MRI in healthcare.
  • Significant Economic Benefits: Research from Jefferson Abington Hospital shows that the use of the Swoop® system not only improved patient care but also significantly reduced MRI wait times in the ICU and ED, enhancing hospital operational efficiency and reflecting the economic value of portable MRI.
  • Rapid Application Expansion: CHRISTUS Mother Frances Hospital achieved 500 scans in just nine months, demonstrating the successful integration of the Swoop® system into its stroke program, leading to the purchase of additional equipment to enhance emergency patient care and reduce unnecessary admissions and transport costs.
  • Optimized Diagnostic Workflow: Neurology of Central Florida has completed over 500 in-office MRI scans, with the introduction of the Swoop® system allowing neurologists to finalize diagnostic evaluations within 24 to 72 hours, significantly shortening patient wait times and improving the timeliness of medical decisions.
seekingalpha
8.5
05-26seekingalpha
Hyperfine Expected to Join Russell 2000 Index
  • Index Inclusion Expected: Hyperfine (HYPR) is anticipated to join the Russell 2000 and Russell 3000 indexes after the U.S. market closes on June 26, based on a preliminary list published by FTSE Russell on May 22, indicating increased recognition in the capital markets.
  • Strategic Progress: CEO Maria Sainz stated that this inclusion reflects advancements in the company's commercial strategy and the adoption of its portable MRI technology, suggesting enhanced growth potential moving forward.
  • Strong Financial Performance: In its Q1 2026 earnings report, Hyperfine reported revenue of $3.90 million, exceeding market expectations by $0.37 million, while the GAAP EPS of -$0.09 indicates a solid gross margin of 50%-55%, showcasing robust profitability.
  • Future Revenue Targets: Hyperfine has set a revenue target of $20 million to $22 million for 2026, demonstrating confidence in future growth and reflecting its ongoing innovation and market expansion capabilities in the healthcare technology sector.
Newsfilter
3.5
05-22Newsfilter
Portable MRI Study Shows Efficiency in Emergency Care
  • Clinical Trial Results: At the 2026 Annual Meeting of the Society for Academic Emergency Medicine, Hyperfine presented results from the PRIME study, demonstrating that portable MRI significantly enhances imaging efficiency in emergency departments by reducing the median time from imaging order to scan start from 7.76 hours to 1.28 hours, a difference of 6.35 hours, highlighting its potential value in urgent situations.
  • Critical Pathology Detection: Among completed scans, 18.6% revealed critical pathologies such as acute ischemic stroke and mass lesions, which were successfully detected by portable MRI and confirmed by conventional MRI, underscoring its importance in rapid diagnosis.
  • Workflow Optimization: The study indicates that portable MRI can be integrated into emergency department workflows more swiftly, alleviating patient boarding delays associated with waiting for conventional MRI, thereby enhancing overall care efficiency for emergency teams.
  • Future Development Potential: Hyperfine's Swoop® system, by providing faster imaging services, may transform emergency medicine, assisting clinicians in accessing actionable imaging information sooner and advancing the field of emergency neuroimaging.
seekingalpha
9.5
05-13seekingalpha
Hyperfine, Inc. Reports Q1 2026 Earnings Highlights
  • Significant Revenue Growth: Hyperfine reported Q1 2026 revenue of $3.9 million with a gross margin of 51%, demonstrating effective execution in both growth and cost control, thereby enhancing its competitive position in the market.
  • International Expansion Progress: The company obtained CE and UKCA marks for its next-generation Swoop system and DWI Optive AI software, with plans to launch in Europe in Q3, further broadening its international business footprint.
  • Increased Product Adoption: The advanced DWI Optive AI software is now implemented in most scanners, with unit sales rising from 6 to 10 compared to the prior year, indicating accelerated penetration in the large customer market.
  • Stable Financial Outlook: Management reiterated full-year revenue expectations between $20 million and $22 million, with gross margins projected to remain between 50% and 55%, and cash burn controlled at $26 million to $28 million, reflecting confidence in future performance.
Wall Street analysts forecast HYPR stock price to rise
1 Analyst Rating
Wall Street analysts forecast HYPR stock price to rise
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.000
sliders
Low
2.00
Averages
2.00
High
2.00
Current: 0.000
sliders
Low
2.00
Averages
2.00
High
2.00
B. Riley
Yuan Zhi
NULL
to
Buy
upgrade
$2
AI Analysis
2026-05-13
Reason
B. Riley
Yuan Zhi
Price Target
$2
AI Analysis
2026-05-13
upgrade
NULL
to
Buy
Reason
B. Riley analyst Yuan Zhi raised the firm's price target on Hyperfine to $2 from $1.60 and keeps a Buy rating on the shares.
BTIG
Buy
initiated
$2
2026-04-29
Reason
BTIG
Price Target
$2
2026-04-29
initiated
Buy
Reason
BTIG initiated coverage of Hyperfine with a Buy rating and $2 price target. The company's Swoop System enables point-of-care brain MRI at the bedside, expanding access to MRI imaging by eliminating the need for a shielded room, specialized staff, and patient transport, and the next-generation Swoop V2, cleared in May 2025, paired with the 11th-generation Optive AI software release in December 2025, offers a significant step forward in image quality and clinical utility, the analyst tells investors in a research note.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for HYPR
Unlock Now

Valuation Metrics

The current forward P/E ratio for Hyperfine Inc (HYPR.O) is 0.00, compared to its 5-year average forward P/E of -2.00. For a more detailed relative valuation and DCF analysis to assess Hyperfine Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.00
Current PE
0.00
Overvalued PE
-0.85
Undervalued PE
-3.15

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.78
Current EV/EBITDA
-1.81
Overvalued EV/EBITDA
1.04
Undervalued EV/EBITDA
-2.60

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
7.41
Current PS
4.91
Overvalued PS
15.72
Undervalued PS
-0.90

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

swingmax recommendation stocks
Intellectia · 494 candidates
Rsi Category: moderateRelative Vol: >= 1.20Moving Average Relationship: PriceAboveMA5, PriceAboveMA20Is Optionable: TrueOption Sentiments: BullishMacd: positive, bullish
Ticker
Name
Market Cap$
top bottom
INMB logo
INMB
INmune Bio Inc
35.89M
FCUV logo
FCUV
Focus Universal Inc
3.11M
CTRN logo
CTRN
Citi Trends Inc
528.45M
HYPR logo
HYPR
Hyperfine Inc
144.93M
BMBL logo
BMBL
Bumble Inc
354.77M
BCRX logo
BCRX
BioCryst Pharmaceuticals Inc
2.54B
need penny stocks Formed two bottoms
Intellectia · 130 candidates
Price: $0.50 - $5.00Moving Average Relationship: PriceAboveMA5, PriceAboveMA20, PriceCrossAboveMA20Candlestick Pattern: InverseHeadAndShoulder, AscendingTriangle, WhiteCandlestick, LowerShadowSupport Resistance Relationship: PriceBreakResistance, PriceAroundSupport
Ticker
Name
Market Cap$
top bottom
LNKS logo
LNKS
Linkers Industries Ltd
4.31M
CDT logo
CDT
CDT Equity Inc
4.96M
APWC logo
APWC
Asia Pacific Wire & Cable Corporation Ltd
82.05M
NEOV logo
NEOV
NeoVolta Inc
157.37M
EXFY logo
EXFY
Expensify Inc
150.44M
KALA logo
KALA
KALA BIO Inc
67.11M
take me to stock radar
Intellectia · 53 candidates
Region: USPrice: $1.00 - $30.00Volume: >= 1,000,000Price Change Pct: $-25.00 - $25.00Relative Vol: >= 2List Exchange: XNYS, XNAS
Ticker
Name
Market Cap$
top bottom
SATL logo
SATL
Satellogic Inc
729.00M
HUYA logo
HUYA
HUYA Inc
1.01B
GNTA logo
GNTA
Genenta Science SPA
30.70M
ATOM logo
ATOM
Atomera Inc
105.50M
BAER logo
BAER
Bridger Aerospace Group Holdings Inc
173.85M
UROY logo
UROY
Uranium Royalty Corp
683.86M

Whales Holding HYPR

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Hyperfine Inc (HYPR) stock price today?

The current price of HYPR is 1.22 USD — it has decreased -3.94

What is Hyperfine Inc (HYPR)'s business?

Hyperfine, Inc. is a health technology company. The Company is engaged in providing patient care globally through artificial intelligence (AI)-powered portable ultra-low-field (ULF) magnetic resonance (MR) brain imaging. Its Swoop Portable MR Imaging System (Swoop system) produces images at a lower magnetic field strength than conventional magnetic resonance imaging (MRI) scanners. Its Swoop system is designed to transform brain MR for the patient, the clinician and the provider, enabling a highly differentiated experience for patients, timely imaging for clinicians, and favorable economics for hospital administrators. The Swoop system is a portable ULF MRI device for producing images that display the internal structures of the head where full diagnostic examination is not clinically practical. The Swoop system is FDA-cleared for brain imaging of patients of all ages. The Swoop system is commercially available in a select number of international markets.

What is the price predicton of HYPR Stock?

Wall Street analysts forecast HYPR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HYPR is2.00 USD with a low forecast of 2.00 USD and a high forecast of 2.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Hyperfine Inc (HYPR)'s revenue for the last quarter?

Hyperfine Inc revenue for the last quarter amounts to 3.90M USD, increased 82.64

What is Hyperfine Inc (HYPR)'s earnings per share (EPS) for the last quarter?

Hyperfine Inc. EPS for the last quarter amounts to -0.09 USD, decreased -25.00

How many employees does Hyperfine Inc (HYPR). have?

Hyperfine Inc (HYPR) has 102 emplpoyees as of July 08 2026.

What is Hyperfine Inc (HYPR) market cap?

Today HYPR has the market capitalization of 121.11M USD.